Melanoma is the most aggressive and lethal form of skin cancer, originating from the malignant transformation of melanocytes—the specialized pigment-producing cells derived from the neural crest that reside primarily within the basal layer of the epidermis. Although melanoma accounts for less than 5% of all skin cancer diagnoses, it is responsible for the vast majority of skin-cancer-related deaths due to its high propensity for early lymphovascular invasion and distant metastasis.
Over the past two decades, the incidence of melanoma has risen steadily worldwide. However, parallel advances in early diagnostic screening, dermoscopy, molecular genetics, and targeted systemic therapies have fundamentally altered the clinical prognosis for patients facing advanced disease.
1. Pathophysiology and Etiology
Melanocarcinogenesis is driven by a complex interplay between environmental exposures, host genetic susceptibility, and somatic driver mutations that alter cellular proliferation and survival pathways.
[ Ultraviolet (UV) Radiation Exposure ]
(Intermittent Intense Sunburns / UVB Adducts)
│
▼
[ Accumulation of DNA Damage in Basal Melanocytes ]
(Inactivation of CDKN2A; Activation of BRAF / NRAS)
│
▼
[ Dysregulation of the MAPK / ERK Pathway ]
(Uncontrolled Melanocytic Proliferation & Survival)
│
┌───────────────────────────────┴───────────────────────────────┐
▼ ▼
[ Radial Growth Phase ] [ Vertical Growth Phase ]
(Horizontal expansion within epidermis/papillary dermis) (Invasion into deep dermis with metastatic potential)
Key Risk Factors
- Ultraviolet (UV) Radiation: Exposure to ultraviolet radiation—particularly intense, intermittent sun exposure leading to blistering sunburns during childhood and adolescence—is the primary environmental risk factor. UV radiation induces direct DNA damage, generating pyrimidine dimers and causing somatic mutations in key regulatory genes.
- Phenotypic Features: Individuals with fair skin (Fitzpatrick skin types I and II), red or light hair, blue or green eyes, freckling, and a high total body nevus count (>50 typical nevi or the presence of atypical/dysplastic nevi) carry significantly higher risk.
- Germline Genetic Mutations: Approximately 5% to 10% of melanomas occur in familial settings. Hereditary predisposition is frequently linked to germline loss-of-function mutations in the CDKN2A gene (encoding the p16INK4a and p14ARF tumor suppressor proteins) or CDK4 mutations.
- Somatic Driver Mutations: Somatic activation of the MAPK (Mitogen-Activated Protein Kinase) signaling cascade occurs in nearly all melanomas. Activating mutations in the BRAF gene—most commonly the BRAF V600E substitution—occur in approximately 40% to 50% of cutaneous melanomas, followed by NRAS (~15–20%) and NF1 mutations.
2. Clinical and Histological Subtypes
Melanoma presents across four major clinical and histological variants, each characterized by distinct growth patterns, anatomical locations, and underlying driver mutations:
[ Cutaneous Melanoma Subtypes ]
│
┌───────────────────────┬───────────────┴───────────────┬───────────────────────┐
▼ ▼ ▼ ▼
[ Superficial Spreading ] [ Lentigo Maligna ] [ Nodular Melanoma ] [ Acral Lentiginous ]
• Most common (~70%) • Sun-damaged skin (elderly) • Lacks radial phase • Palms, soles, nailbeds
• Intermittent sun spots• Slow horizontal growth • Early vertical phase • Unrelated to UV exposure
| Subtype | Relative Frequency | Typical Anatomical Location | Primary Clinical / Biological Features |
|---|---|---|---|
| Superficial Spreading Melanoma | ~70% | Trunk in men; lower extremities in women | Prolonged radial growth phase; associated with pre-existing nevi and BRAF mutations |
| Lentigo Maligna Melanoma | ~10–15% | Chronically sun-damaged skin (face, neck) in elderly | Arises from lentigo maligna (in situ); slow, spreading hyperpigmented macule |
| Nodular Melanoma | ~15% | Any anatomical site | Lacks an identifiable radial phase; enters vertical growth phase early; presents as a dark papule |
| Acral Lentiginous Melanoma | ~5% | Palmar surfaces, plantar feet, subungual nailbeds | Predominant subtype in dark-skinned populations; completely unrelated to UV light |
3. Diagnostic Evaluation and Clinical Assessment
Early identification remains the single most effective intervention for reducing melanoma mortality.
[ Suspicious Pigmented Cutaneous Lesion ]
│
▼
[ Clinical Evaluation via ABCDE Criteria ]
(Asymmetry, Border, Color, Diameter, Evolving)
│
▼
[ Dermoscopic Bedside Examination ]
(Evaluates pigment networks & globule patterns)
│
▼
[ Full-Thickness Excisional Biopsy ]
(Strictly avoid superficial shave biopsy)
The ABCDE Screening Rule
Clinicians utilize the validated ABCDE mnemonic to evaluate suspicious pigmented lesions:
- A – Asymmetry: One half of the lesion does not match the other half.
- B – Border: Irregular, scalloped, notched, or poorly defined borders.
- C – Color: Variegated color patterns, including shades of brown, black, red, white, or blue.
- D – Diameter: Lesions typically >6 mm (the size of a pencil eraser), though smaller melanomas are increasingly recognized.
- E – Evolving: Any dynamic change in size, shape, color, elevation, or new symptoms (itching, bleeding, crusting). The “ugly duckling” sign—a lesion that looks distinctly different from the patient’s remaining nevi—is an important clinical red flag.
Diagnostic Biopsy Protocols
When melanoma is clinically suspected, a full-thickness excisional biopsy with narrow (1–2 mm) margins extending into the subcutaneous fat is mandatory. Partial biopsies (such as superficial shave biopsies) are strictly contraindicated because they disrupt the lesion architecture, making accurate determination of depth impossible.
4. Histopathology, Micro-Staging, and TNM Framework
Histopathological evaluation establishes micro-staging parameters that guide prognosis and surgical planning.
[ Primary Histological Prognosticators ]
│
┌──────────────────────────────────────┴──────────────────────────────────────┐
▼ ▼
[ Breslow Thickness ] [ Ulceration Status ]
• Measured in millimeters from granular layer to deepest tumor cell • Microscopic absence of intact epidermis
• Single most critical prognostic indicator in localized melanoma • Automatically upstages T-category
Critical Micro-Staging Parameters
- Breslow Thickness: The total vertical depth of the tumor measured under a microscope from the top of the epidermal granular layer to the deepest infiltrating melanoma cell in the dermis or subcutis. Breslow thickness is the single most powerful prognostic determinant in primary cutaneous melanoma.
- Ulceration: The microscopic breakdown of the overlying epidermis. The presence of ulceration reflects biologically aggressive tumor growth and automatically shifts the primary tumor category to a higher prognostic tier.
- Mitotic Rate: Expressed as mitoses per square millimeter (mitoses/mm2), signaling active cellular proliferation.
- Perineural / Lymphovascular Invasion: Identifies microscopic tumor invasion into local nerves or blood vessels.
The AJCC Staging System
The American Joint Committee on Cancer (AJCC) stages melanoma using the TNM Classification framework:
[ Stage I / II: Localized Disease ] ➔ Dependent on Breslow thickness ($T1\le1.0\text{mm}$ to $T4>4.0\text{mm}$) & ulceration
[ Stage III: Regional Nodal ] ➔ Spread to regional lymph nodes or in-transit / satellite metastases
[ Stage IV: Distant Metastatic ] ➔ Metastasis to distant skin, soft tissue, lungs, brain, or elevated LDH
- Sentinel Lymph Node Biopsy (SLNB): For primary melanomas with a Breslow thickness >1.0 mm (or ≥0.8 mm with adverse features such as ulceration), SLNB is performed. Radioactive tracer and blue dye map the primary lymphatic basin to identify and excise the first node draining the tumor site, detecting occult microscopic nodal metastases.
Conclusion
Melanoma is an aggressive cutaneous malignancy defined by rapid growth dynamics, variable clinical subtypes, and distinct molecular driver mutations. Through diligent clinical screening using the ABCDE criteria, prompt full-thickness excisional biopsy, accurate measurement of Breslow thickness, and precise AJCC micro-staging, clinical teams can identify melanomas early—maximizing the potential for curative surgical management and optimizing long-term patient outcomes.